Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04041128 · ClinicalTrials.gov registry record · Early Phase 1
PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer
A Early Phase 1 study, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 14
- Enrollment target
NCT04041128 is a Early Phase 1 study that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 14 participants.
The verdict
NCT04041128, a Early Phase 1 study, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 14 participants
- Enrollment target
Study Summary
Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy. This study will administer 7 days of treatment with a targeted therapy called Lynparza. Lynparza and/or other PARP inhibitors have been FDA approved for the treatment of ovarian and breast cancer. Tissue biopsy will be done before a 7 day course of Lynparza in order to correlate molecular changes to response to treatment. Participation in this trial will require an additional tumor biopsy which will occur either before or after treatment of Lynparza.
Interventions
- DRUG Lynparza
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2019-07-23 |
| Est. Completion | 2021-06-15 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04041128
The ClinicalTrials.gov registry entry for NCT04041128 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 14 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Texas Southwestern Medical Center, which has 837 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Lynparza is the first listed.
NCT04041128 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04041128 about?
NCT04041128 is a clinical study titled "PARP Inhibition During Pre-surgical Window in Breast/Ovary Cancer". Study involves surgery for cytoreduction or laparoscopy to determine if you are a candidate for tumor debulking or a tissue biopsy. Following this surgery you will receive chemotherapy. This study will administer 7 days of treatment with a targeted therapy called Lynparza. Lynparza and/or other PARP...
What is the current status of trial NCT04041128?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 14 participants. The study started on 2019-07-23. Estimated completion is 2021-06-15.
What interventions are being tested in trial NCT04041128?
The interventions under investigation include: Lynparza (DRUG).
Who is sponsoring clinical trial NCT04041128?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.